Mukesh Mayani

Dr. Mukesh Mayani is a Senior Director in Global CMC Development for Gene Therapy at Ultragenyx Pharmaceuticals, Inc., based in Woburn, MA, USA. In his current role, Dr. Mayani leads the Purification Development team and overseeing the DS, DP and Formulation activities for late-phase and commercial-ready Gene Therapy programs. Prior to joining Ultragenyx, Dr. Mayani led Upstream, Downstream, and Pilot teams for Gene Therapy Development (PD) and closely worked with CDMO function at Resilience. He also played a key role in AAV and LVV Program Developments within the Gene Therapy CMC organization at Sanofi, USA. Dr. Mayani's earlier experience includes working at Cytiva, Bristol-Myers Squibb (BMS), and Therapure Biopharma (now Resilience), where he contributed to the development of viral vectors, monoclonal antibodies (mAbs), RNA-based vaccines, and other biopharmaceutical modalities. Dr. Mayani holds a PhD in Chemical Engineering and is a licensed Professional Engineer, with nearly 18 ye